Literature DB >> 17925397

IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production.

Gagik Oganesyan1, Supriya K Saha, Eric M Pietras, Beichu Guo, Andrea K Miyahira, Brian Zarnegar, Genhong Cheng.   

Abstract

Hypomethylated CpG oligonucleotides (CpG) are not only potent adjuvants for enhancing adaptive immune responses but may also play a critical role in the development of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Here we provide evidence that, in addition to dendritic cells, murine B lymphocytes also exhibit a type I IFN response to CpG-B. Unlike dendritic cells, B cell-mediated type I IFN induction depended on the transcription factor IRF3, but similar to dendritic cells this pathway was independent of the IRF3 kinase TBK1. Utilizing type I IFN receptor-deficient mice, we were able to demonstrate that this IFN pathway enhanced Syndecan-1 expression and IgM production and was required for IgG2a production following CpG-B stimulation. Overall, our findings identify a unique IFN pathway in B cells that may play a central role in mediating B cell biology in response to CpG, potentially implicating this pathway in autoantibody production and the pathogenesis of certain autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925397     DOI: 10.1074/jbc.M704755200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.

Authors:  Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

2.  Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Authors:  Ming You; Guanjun Dong; Fanlin Li; Feiya Ma; Jing Ren; Yujun Xu; Huimin Yue; Ruijing Tang; Deshan Ren; Yayi Hou
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

3.  Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.

Authors:  David A Savitsky; Hideyuki Yanai; Tomohiko Tamura; Tadatsugu Taniguchi; Kenya Honda
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Regulation of humoral immunity by gut microbial products.

Authors:  Myunghoo Kim; Chang H Kim
Journal:  Gut Microbes       Date:  2017-02-28

Review 5.  Role of type I interferons in the activation of autoreactive B cells.

Authors:  Kerstin Kiefer; Michael A Oropallo; Michael P Cancro; Ann Marshak-Rothstein
Journal:  Immunol Cell Biol       Date:  2012-03-20       Impact factor: 5.126

6.  Deleting key autophagy elongation proteins induces acquirement of tumor-associated phenotypes via ISG15.

Authors:  EunBin Kong; Hag Dong Kim; Joon Kim
Journal:  Cell Death Differ       Date:  2020-03-03       Impact factor: 15.828

7.  TRAF5 is a downstream target of MAVS in antiviral innate immune signaling.

Authors:  Eric D Tang; Cun-Yu Wang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

8.  A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

Review 9.  Interferon regulatory factor 3 in adaptive immune responses.

Authors:  Laure Ysebrant de Lendonck; Valerie Martinet; Stanislas Goriely
Journal:  Cell Mol Life Sci       Date:  2014-05-31       Impact factor: 9.261

10.  Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop.

Authors:  Nathaniel M Green; Amy Laws; Kerstin Kiefer; Liliana Busconi; You-Me Kim; Melanie M Brinkmann; Erin Hodges Trail; Kei Yasuda; Sean R Christensen; Mark J Shlomchik; Stefanie Vogel; John H Connor; Hidde Ploegh; Dan Eilat; Ian R Rifkin; Jean Maguire van Seventer; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.